Determinations of serum tumor necrosis factor alpha in corneal allografts

Ocular Immunology and Inflammation

Volumn 5, Issue 3, 1997, Pages 149-155

  Pleyer, Uwe ^a,b   Milani, Jessica K ^a   Rückert, Dieter ^c   Rieck, Peter ^b   Mondino, Bartly J ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Graft rejection; Keratoplasty; Transplantation; Tumor necrosis factor alpha

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; IMMUNOREACTIVITY; KERATOPLASTY; NONHUMAN; PROTEIN BLOOD LEVEL; RAT;

EID: 0030863595     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.3109/09273949709116889     Document Type: Article

References (24)

1. Cunningham DA, Dunn MJ, Yacoub MH, Rose ML. Local production of cytokines in the human cardiac allograft.Transplantation 1994; 57: 1333-1337.
2. Chollet-Martin S, Depoix JP, Hvass Y. Raised plasma levels of tumor necrosis factor in heart allograft rejection. Transplant Proc 1990; 22: 283-285.
3. Imagawa DK, Millis JM, Olthoff KM. The role of tumor necrosis factor in allograft rejection. I: Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation 1990; 50: 219-225.
4. McLaughlin PJ, Aikawa A, Davies HM, Ward RG, Bakran A, Sells RA, Johnson PM. Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients. Transplantation 1991; 51: 1225-1229.
5. Scheringa M, deBruin RWF, Jeekel H, Marquet RL. Anti-tumor necrosis factor alpha serum prolongs heart allograft survival in rats. Transplant Proc 1991; 23: 547-548.
6. Gill TJ, Kunz HW, Misra DN, Hassett ALC. The major histocompatibility complex of the rat. Transplantation 1987; 43: 773-785.
7. Williams KA, Coster DJ. Penetrating corneal transplantation in the inbred rat: a new model. Invest Ophthalmol Vis Sci 1985; 26: 23-30.
8. Pleyer U, Milani JK, Dukes A, Chou HJ, Rückert D, Schmidt KH, Mondino BJ. Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci 1995; 26: 23-30.
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
10. Auchincloss H, Sultan H. Antigen processing and presentation in transplantation. Curr Opin Immunol 1996; 8: 681-687.
11. Cantrell DA, Smith KA. Transient expression of interleukin-2 receptors: consequences for T-cell growth. J Exp Med 1983; 158: 1895-1898.
12. Economou JS, McBride WH, Essner R , Rhoades K, Golub S, Holmes EC, Morton DL. Tumor necrosis factor production by interleukin-2 activated macrophages in vitro and in vivo. Immunology 1989; 67: 514-519.
13. Foster CS, Wu HK, Merchant A. Systemic serum soluble interleukin-2 receptor levels in corneal transplant recipients. Doc Ophthalmol 1993; 83: 83-90.
14. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: Biology, function and clinical application. Ann Int Med 1990; 113: 619-627.
15. Michie HR, Manogue KR, Spriggs DR, Revaug A, o'Dwyer S, Dinarello CA. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-1486.
16. Tracey KJ, Lowry SF, Cerami A. Physiological responses to cachectin. In: Bock G, Marsh (eds). Tumor necrosis factor and related cytotoxins. New York: Wiley, 1987; p 88.
17. Männel D, Murray C, Risau W, Clauss M. Tumor necrosis: factors and principles. Immunol Today 1996; 17: 254-256
18. Callanan D, Peeler J, Niederkorn JY. Characteristics of rejection of orthotopic corneal allografts in the rat. Transplantation 1988; 45:437-443.
19. Leroux-Roels G, Offner F, Phillipe J, Vermeulen A. Influence of blood collecting systems on concentrations of tumor necrosis factor in serum and plasma. Clin Chem 1988; 34: 2373-2374
20. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cyctotoxic T cell development by transforming growth factor-beta and reversal by recombinant tumor necrosis factor-alpha. J Exp Med 1987; 166: 991-998.
21. Fomsgaard A, Svenson M, Bendtzen K. Autoantibodies to tumor necrosis factor alpha in healthy humans and patients with inflammatory disease and gram-negative bacterial infections. Scand J Immunol 1989; 30: 219-223.
22. Nishi M, Matsubara M, Sugawara I, Mori S, Mochizuki M. An immunohistochemical study of rejection process in a rat penetrating keratoplasty model. In: Usui M, Ohno S, and Aoki K (eds). Ocular Immunology Today. Elsevier Science Publishers 1990; pp 99-102.
23. Van der Veen G, Broersma L, Dijkstra CD, Van Rooijen N, Van Rij G, Van der Gaag R. Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest Ophthalmol Vis Sci 1994; 35: 3505-3515.
24. Pleyer U, Steuhl KP, Weidle EG, Lisch W, Thiel HJ. Corneal graft rejection: incidence, manifestation and interaction of clinical subtypes. Transplant Proc 1992; 24: 2034-2037.